Copaxone Approved by FDA for Patients With Signs of Multiple Sclerosis

Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration has approved an expanded indication for COPAXONE (glatiramer acetate injection) to include the treatment of patients who have experienced a first clinical episode and have magnetic resonance imaging features consistent with multiple sclerosis (MS).
MarketWatch